References
Abraham PH, Choa RG, Gaches CGC, Ashken MH, Green NA (1981) A controlled trial of single dose intravesical Adriamycin in superficial bladder tumors. Br J Urol 53: 585
Andersson C, Johansson C, Nilsson S (1980) The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J Urol 124: 23
Andriole GL (1992) Intravesical therapy for superficial bladder cancer. Curr Opin Urol 2: 375
Aso Y, Anderson L, Soloway M, Bouffioux C, Chisolm G, Debruyne F, Kawai T, Kurth KH, Maru A, Straffon WGE (1986) Prognostic factors in superficial bladder cancer. In: Denis L, Niijima T, Prout G, Schroeder FH (eds) Development in bladder cancer. Alan R. Liss, New York, p 257
Badalament RA, Ortolano V, Burgers JK (1992) Recurrent or aggressive bladder cancer. Urol Clin North Am 19: 485
Blinst Italian Cooperative Group (1984) Intravesical doxorubicin for the prophylaxis of superficial bladder tumors. Cancer 54: 756
Bracken RB, Swanson D, Defuria D, Crooke S (1980) Role of intravesical mitomycin-C in management of superficial bladder tumors. Urology 16: 11
British Medical Council (1983) The effect of intravesical thiothepa on the recurrence rate of newly diagnosed superficial bladder cancer. Br J Urol 57: 680
Burk K, Droller RM, Herold W, Pittner P (1984) Recurrence prophylaxis in superficial bladder tumors with adriamycin. In: Denis L, Murphy GP, Prout GR, Schroeder FH (eds) Controlled clinical trials in urologic oncology Raven, New York, p 291
Calais da Silva F, Denis L, Bono A, Bollack C, Bouffioux C (1988) Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors. Eur Urol 14: 207
Colleen S, Ek A, Hellsten S, Lindhollm CE (1980) Intracavitary Epodyl for multiple non-invasive highly differentiated bladder tumors. Scand J Urol Nephrol 14: 43
Cutler SJ, Heney NM, Friedell GH (1982) Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: Bonney WW (ed) AUA monographs: bladder cancer. Williams & Wilkins, Baltimore, p 35
Cutler SJ, Heney NM, Friedell GH (1982) Factors associated with disease recurrence and progression. In: Bonney WW, Prout GR (eds) Bladder cancer, vol 1. Williams & Wilkins, Baltimore, p 35
Dalesio O, Schulman CC, Sylvester R, De Pauw M, Robinson M, Denis L, Smith P, Viggiano G (1983) Prognostic factors in superficial bladder tumor. A study of the EORTC GU Group. J Urol 129: 730
Defuria MD, Bracken RB, Johnson DE, Soloway MS, Merrin CE, Morgan LR, Miller HC, Crooke ST (1980) Phase I–II study of mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep 64: 225
Devonec M, Bovier R, Sarkassian J, Bendimerand O, Gelet A, Dubernard JM (1983) Intravesical instillation of mitomycin-C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder. Br J Urol 55: 382
Edsmyr F, Boman J (1970) Instillation of thiothepa (Tifosyl) in vesical papillomatosis. Acta Radiol [Oncol] 9: 395
Ek A, Hellsten S, Henrikson H, Idwall I, Lindholm CE, Lindholm K, Mikulowski P, Mansson W (1984) Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder. Scand J Urol Nephrol 18: 131
Flamm J (1990) Long term versus short term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur Urol 17: 119
Flamm J, Bucher A, Hoeltl W (1990) Recurrent superficial transitional cell carcinoma of the bladder. Adjuvant topical chemotherapy versus immunotherapy. J Urol 144: 260
Garnick MB, Schade D, Israel M, Mexwell B, Richie JP (1984) Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder cancer. J Urol 131: 43
Glashan RW (1983) Treatment of carcinoma in situ of the bladder with doxorubicin (Adriamycin). Cancer Chemother Pharmacol 11 [Suppl]: S35
Glashan WA (1990) A randomised controlled study of intravesical alpha 2b interferon in carcinoma in situ of the bladder. J Urol 144: 658
Green DF, Robinson MRG, Glashan R, Newling D, Dalesio O, Smith PH (1984) Does intravesical chemotherapy prevent invasive bladder cancer? J Urol 131: 33
Gustafson H, Tribukait B, Esposti PL (1982) DNA pattern, histological grade and multiplicity related to recurrence rate in superficial bladder tumors. Scand J Urol Nephrol 16: 135
Heney NM (1992) Natural history of superficial bladder cancer. Urol Clin North Am 19: 429
Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder M, Haferman MD, Hawkins IR (1983) Superficial bladder cancer. Progression and recurrence. J Urol 130: 1083
Herr HW (1991) Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guérin. J Urol 145: 40
Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF (1989) Superfical bladder cancer treated with bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression. J Urol 141: 22
Huland H, Otto U (1983) Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Eur Urol 9: 84
Huland O, Kloppel G, Feddersen I, Otto U, Brachman W, Hubman H, Kaufmann J, Knipper W, Lantius-Beninga H, Huland E (1990) Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 144: 68
Issel BF, Prout GR, Soloway MS, Cummings KB, Brannen G, Veenema R, Flanagan M, Block NL, Summers JL, Levin EA, Defuria MC (1984) Mitomycin-C intravesical therapy in noninvasive bladder cancer after failure of thiothepa. Cancer 53: 1025
Jakse G (1985) Intravesical chemotherapy for carcinoma of the bladder — duration of the treatment course. In: Schroeder FH, Richards B (eds) Superficial bladder tumors. Alan R. Liss, New York, p 69
Jakse G, Hofstaedter F, Marberger H (1984) Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a follow up. J Urol 131: 41
Jakse G, Hall R, Bono A, Hoeltl W, Carpenter P, De Pauw M, Sylvester R (1992) Intravesical BCG in patients with carcinoma in situ of the urinary bladder. First results of the EORTC GU Group protocol 30861. In: Villavencio H, Fair WR (eds) Evaluation of chemotherapy in bladder cancer. SIU/Churchill-Livingstone. Edinburgh, p 13
Jurincic C, Stoecker W, Markl J, Engelmann U, Gasch J, Klippel KF (1990) Immunotherapy with keyhole-limpet hemocyanin (KLH) as prophylaxis against superficial bladder tumor recurrence. In: deKernion JB (ed) Immunotherapy of urological tumors. Churchill Livingstone, Edinburgh, p 139
Kaye KW, Lange PH (1982) Mode of presentation of invasive bladder cancer. J Urol 135: 265
Koontz WW, Prout GR, Smith W, Frable WJ, Minnis JE (1981) The use of intravesical thiothepa in the managment of non invasive carcinoma of the bladder. J Urol 125: 307
Kotake T, Akaza H, Niijima T (1992) Prophylactic intravesical instillation chemotherapy for superficial bladder cancer. In: Villavencio H, Fair WR (eds) Evaluation of chemotherapy in bladder cancer. SIU/Churchill Livingstone, Edinbrugh, p 1
Kurth KH (1984) Superficial TCC bladder cancer: the impact of tumor differentiation on recurrence, progression and survival. In: Küss R, Khoury S, Denis LJ, Murphy GP (eds) Bladder cancer, part A. Alan R. Liss, New York, p 307
Kurth KH, Maksimovic PA, Hop WCJ, Schroeder FH, Bakker NJ (1983) Single dose intravesical epodyl after TUR of Ta TCC bladder carcinoma. World J Urol 1: 89
Kurth KH, Schroeder FH, Tunn U, Ay R, Pavone-Macaluso M, Debruyne F, De Pauw M, Daleio O, Ten Kate F (1989) Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of an EORTC randomised trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J Urol 132: 258
Kurth KH, Sylvester R, De Pauw M, ten Kate F (1989) Intracavitary treatment of transitional cell carcinoma of the bladder. Questions and lessons after 27 years of experience. In: Debruyne FMJ, Denis L, Meijden ADM, van der (eds) BCG in superficial bladder tumors. Alan R. Liss, New York, p 145
Kurth KH, Vijgh WJF, Kate F ten, Bogdanowicz JF, Carpenter PJ, Reyswoud I van (1991) Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J Urol 146: 1508
Lamm DL, Crissman J, Blumenstein B, Crawford ED, Montie J, Scardino P, Grossman HB, Stanisic T, Smith J, Sullivan J, Sarosdy M (1989) Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group study. In: Debruyne FMJ, Denis L, Meijden APM, van der (eds) BCG in superficial bladder cancer. Alan R. Liss, New York, p 263
Loening S, Narayana A, Yoder L (1980) Factors influencing the recurrence rate of bladder cancer. J Urol 123: 29
Lutzeyer W, Rubben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127: 250
Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L, Fiter L, Mosteiro JA, Navarro J, Garcia Matres MJ, Carcamo P (1989) Intravesical therapy comparing BCG, Adriamycin and thiothepa in 200 patients with superficial bladder cancer. A randomized study. In: Debruyne FMJ, Denis L, Meijden APM van der (eds) BCG in superficial bladder cancer. Alan R. Liss, New York, p 237
Matsumura Y, Ozaki Y, Ohmori H, OUCCG (1983) Intravesical adriamycin chemotherapy in bladder cancer. Cancer Chemother Pharmacol 11 [Suppl]: S69
Matsumura Y, Tsushima T, Ozaki Y (1987) Intravesical chemotherapy with 4′-epi-adriamycin in patients with superficial bladder tumors. Cancer Chemother Pharmacol 16: 176
Mishina T, Oda K, Murata S, Ooe H, Mori Y, Takahashi T (1975) Mitomycin-C bladder instillation therapy for bladder tumors. J Urol 114: 217
Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116: 180
Murphy WM, Chandler RW, Trafford RM (1986) Flow cytometry of deparaffinized nuclei compared to histological grading for the pathological evaluation of transitional cell carcinomas. J Urol 135: 694
Nieh PT, Daly JJ, Heaney JA, Heney NM, Prout GR (1978) The effect of intravesical thiothepa on normal and tumor urothelium. J Urol 119: 59
Niijima T (1978) Intravesical therapy with Adriamycin and new trends in the diagnostics and therapy of superficial bladder tumors. In: WHO (eds) Diagnosis and treatment of superficial urinary bladder tumors. WHO, Stockholm, p 37
Niijima T, Akaza H, Koisok K (1983) Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11 [Suppl]: S79
Ozaki Y, Tsushima T, Nasu Y, Akagi T, Matsumura Y, Ohomori H (1986) Prophylactic intravesical instillation therapy with Adriamycin (ADM) and mitomycin C (MMC) in patients with superficial bladder cancer. Jpn J Urol 77: 1493
Pagano F, Bassi PF, Milani C, Meneghini A, Tuccitto G, Grabeglio A, Guazzeri S (1989) Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results. In: Debruyne FMJ, Denis L, Meijden APM van der (eds) BCG in superficial bladder cancer. Alan R. Liss, New York, p 253
Parmar MKB, Freedman LS, Hargreave JB, Tolley DA (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Subgroup). J Urol 142: 284
Prout GR, Koontz WW, Coombs LJ, Hawkins IR, Friedell GH (1983) Long term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not receive thiothepa. J Urol 130: 677
Prout GR, Barton BA, Griffin P, Friedell GH (1992) Treated history of non-invasive grade 1 transitional cell carcinoma. J Urol 148: 1413
Riddle PR (1991) Carcinoma in situ of the bladder. In: Alderson AR, Oliver RTD, Hanham IWF, Bloom HJG (eds) Urological oncology. John Wiley & Sons, Chichester, p 89
Rubben H, Lutzeyer W, Fischer N, Detuz F, Lagrange W, Giani G, members of the Registry for Urinary Tract Tumors, RWTH, Aachen (1988) Natural history and treatment of low risk and high risk superficial bladder tumors. J Urol 139: 283
Sarosdy MF (1992) Principles of intravesical chemotherapy and immunotherapy. Urol Clin North Am 19: 509
Schulman CC (1982) Intravesical chemotherapy for superficial bladder tumors. In: Denis L, Smith PH, Pavone-Macaluso M (eds) Clinical bladder cancer. Plenum, New York, p 101
Schulman CC, Denis I, Oosterlinck W, Sy W de, Chantrie M, Bouffioux C, Van Cangh P (1982) Early adjuvant adriamycin in superficial CTC of the bladder: a preliminary report. Chemiotherapia 4: 275
See WA, Chapman WH (1987) Tumor cell implantation following Nd: YAG bladder injury. A comparison to electrocautery injury. J Urol 137: 1266
Smith G, Elton RA, Benyon LL, Newsham JE, Chisholm GD, Hargreave JB (1983) Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 55: 665
Smith JA (1991) Laser surgery for transitional-cell carcinoma. Urol Clin North Am 19: 473
Smith PH (1991) The role of intravesical chemotherapy in superficial bladder cancer. In: Alderson AR, Oliver RTD, Hanham IW, Bloom HJG (eds) Urological oncology: dilemmas and development. Wiley & Sons, Chichester, p 95
Soloway MS, Masters S (1979) Implantation of transitional tumor cells on the cauterized murine endothelial surface. Proc Am Soc Clin Oncol 20: 256
Tsushima T, Matsumura Y, Ozaki Y, Yoshimoto J, Ohmori H, OUCCG (1987) Prophylactic intravesical instillation therapy with adriamycin and mitomycin-C in patients with superficial bladder cancer. Cancer Chemother Pharmacol 20 [Suppl]: S72
Utz DC, Hanash KA, Farrow GM (1970) The plight of the patient with carcinoma in situ of the bladder. J Urol 103: 160
Van der Meijden APM, Kurth KH, Oosterlinck W, Sylvester R (1993) Prognostic factors in superficial bladder cancer: consequences for therapy and follow-up. In: Murphy G, Khoury S, Chatelain C, Denis L (eds) Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer. Diagnosis and treatment. SCI, Jersey, p 352
Varkarakis MJ, Gaeta J, Moore RH (1974) Superficial bladder tumor: aspects of clinical progression. Urology 4: 414
Williams RD (1990) Intravesical alpha interferon in the treatment of superficial bladder cancer. In: deKernion JB (ed) Immunotherapy of bladder tumors, Churchill Livingstone, Edinburgh, p 121
Worf H, Hojgaard K (1983) Urothelial dysplasia concomitant with bladder tumors as a determinant for future new occurrences. Lancet II: 134
Xie T, Xu D, Zhu J (1992) Long-term follow-up of camptothecin instillation for prevention and treatment of urinary bladder tumors. In: Villavencio H, Fair WR (eds) Evaluation of chemotherapy in bladder cancer. SIU/Churchill Livingstone, Edinburgh, p 37
Zincke H, Utz DC, Taylor WF, Meyers RP, Leary FJ (1983) Influence of thiothepa and doxorubicin instillation at the time of transurethral surgical treatment of bladder cancer on tumor recurrence; a prospective randomized double-blin controlled trial. J Urol 129: 505
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bono, A.V. Superficial bladder cancer: state of the art. Cancer Chemother. Pharmacol. 35 (Suppl 1), S101–S109 (1994). https://doi.org/10.1007/BF00686931
Issue Date:
DOI: https://doi.org/10.1007/BF00686931